On Friday, Intercept Pharmaceutical reached a key performance benchmark, with its Relative Strength (RS) Rating rising into the 90-plus percentile with an upgrade to 93, a rise from 89 the day before.
When you're researching the best stocks to buy and watch, be sure to pay attention to relative price strength. IBD's proprietary rating identifies market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the last 52 weeks compares to all the other stocks in our database.
Over 100 years of market history reveals that the top-performing stocks typically have an 80 or higher RS Rating at the beginning of a new run.
Looking For The Best Stocks To Buy And Watch? Start Here
Is Intercept Pharmaceutical Stock A Buy?
Intercept Pharmaceutical is building a with a 20.10 buy point. See if it can clear the breakout price in heavy trade. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
Earnings grew 10% last quarter, up from 0% in the prior report. Revenue also increased, from 3% to 5%.
Intercept Pharmaceutical stock earns the No. 50 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharma, Vertex Pharmaceuticals and Genmab are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
